ClinicalTrials.gg

Program

ganfeborole

In GlaxoSmithKline's pipeline, Leucyl t-RNA synthetase inhibitor. Its studies are mostly in Tuberculosis, Pulmonary · Tuberculosis, led by GlaxoSmithKline.

Furthest: phase 2, since Jun 4, 20184 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline40 open or runningphase 2since Jun 4, 2018Mar 6, 2017none ahead
  • Named in GlaxoSmithKline’s own pipeline as ganfeborole GSK3036656, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2017First study: phase 1 study in TuberculosisFirst studyNCT03075410 · 30 enrolled · United Kingdom
  2. Jun 4, 2018Phase 2 study in TuberculosisNCT03557281 · 76 enrolled · South Africa
  3. May 16, 2022Phase 2 study in TuberculosisNCT05382312 · 127 enrolled · South Africa
  4. Apr 3, 2024Phase 1 study in TuberculosisNCT06354257 · 20 enrolled · Spain

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Leucyl t-RNA synthetase inhibitor”the company's pipeline, read by Claude · source

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06354257Tuberculosis · Spain1CompletedJul 1, 202420
NCT05382312Tuberculosis · South Africa2CompletedMay 27, 2025127
NCT03557281Tuberculosis · South Africa2CompletedDec 3, 202176
NCT03075410Tuberculosis · United Kingdom1CompletedAug 4, 201730

How it is read

Names in the registry

  • “GSK3036656”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.